The Consortium

The Consortium

NanoGrowSkin is a transversal research project that combines regenerative medicine technologies with nanomedicine products, in a transnational collaboration of public research groups from academia clinical/public health research sector and private companies.

  • ibs.GRANADA, Spain (Clinical/public health research sector) owns the patent of the production of fibrin-agarose based artificial tissues, having a strong technical experience on the manufacturing of bioartificial skin substitutes in compliance with GMP standards.
  • OSI Health XXI, Spain (Large enterprise) has been developing an efficient nanoparticle delivery system to carry different molecules, such as growth factors and antibiotics.
  • IBI – Istituto Biochimico Italiano Giovanni Lorenzini, Italy (Large enterprise) has a well-established know how on formulation development and GMP production, so they will be in charge of the scale-up of antibiotic-loaded NPs and GMP batches preparation.
  • University of Bordeaux, France (Academia). INSERM U1035 will provide his wound healing knowledge to characterize and analyze the interaction between NPs and the bioengineered human skin substitute.
  • University of Compiègne, France (Academia) has created human skin models and they will study the preclinical toxicology of NPs with both growth factors and antibiotics.
  • NUI Galway, Ireland (Academia) has developed a modified fibrin scaffold to deliver therapeutic biomolecules for wound healing applications.

The Partners

Miguel Alaminos


Tissue engineering research group, ibs.GRANADA (Project Coordinator)

The Tissue Engineering Group is a pioneer group in Tissue Engineering. It is a consolidated multidisciplinary research group, composed of both basic and clinical researchers. The group is focused on the development of human bioengineered organs and tissues by tissue engineering, functionalization of biocompatible hydrogels and cell differentiation and transdifferentiation for use in tissue engineering. The group has developed different models of artificial tissues for clinical use, and some of these models have been grafted in patients and evaluated clinically. The research activity of the group gave rise to 8 patents related to new biomaterials and nanotechnology-based engineering techniques. Likewise, the group has established quality control protocols endorsed at an international level.

Miguel Alaminos (Project Coordinator), MD, PhD, BSc, PhD obtained a Doctoral Degree in Biology in 2000 and a Doctoral Degree in Medicine in 2001 at the University of GRANADA, Spain, and a Specialization Degree in Pediatric Surgery at the University Hospital Virgen de las Nieves, GRANADA, Spain. He has postdoctoral research experience in molecular pathology, cell culture, microarray and epigenetics, with postdoctoral stays at Memorial Sloan Kettering Cancer Center in New York and CNIO in Madrid. Then, he joined the Tissue Engineering Group at the University of GRANADA in 2004, and got his current position as University Professor of Histology and Tissue Engineering in 2012. To the date, M. Alaminos has participated in more than 30 granted research projects, being IP of 15 of them. Most of these projects are focuses on the generation and characterization of different bioengineered human tissues using human cell cultures and natural biomaterials: general tissue engineering (including primary cell culturing, biomaterials development and experimental surgery), cornea tissue engineering, oral mucosa tissue engineering, nervous system, and docent innovation projects (teaching and learning strategies in tissue engineering). All these projects were successful and gave rise to numerous research manuscripts and international congress presentations.

Other researchers of Tissue Engineering Group involve in NanoGSkin Project are Antonio Campos Muñoz, Ingrid Garzón Bello, Víctor Sebastián Carriel Araya.

Maria Villar-Vidal


OSI Health XXI – Keralty

We are a value focused health company consisting of health insurance, health services and hospital and provider health care delivery organizations. We are a group committed to the health of our members, keeping them healthy, focusing on prevention and the identification and management of health risks and diseases. Keralty’s social engagement results on academic, social and research projects and initiatives in order to contribute to the welfare and knowledge progress in those communities where it operates.

In our company research constitutes an essential part of high level knowledge (know-how) generation and

we seek to promote research and give visibility in different contexts. Keralty collaborates with other companies and R&D&i institutions worldwide and develops projects under demand, offering research guidance and advice. The main R&D research areas in Keralty are:

Regenerative Medicine and Advanced Therapies, Personalized Medicine, Infectious diseases, Chronicity and neurodegenerative Diseases, Oncology, Primary Care and education and eHealth. Also Health Value, Big Data and Health Technology Assessment are three common areas of interest.

Maria has a PhD Microbiology by the Faculty of Medicine of the University of the Basque Country and a degree in Management. She also holds a Certification of the Basque University Quality System as Assistant Professor in Biological Sciences. She has 15 years of experience in international collaborative projects and in 2015, she joined as coordinator of the R&D within the Organization being involved mostly in the early Health Technology Assessment and personalized medicine. She is also External Expert in COST Actions European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe and reviewer in several publications.

Loredana Cecchetelli


Giovanni Esposito


Istituto Biochimico Italiano Giovanni Lorenzini S.p.A., Research&Development

Istituto Biochimico Italiano (IBI) is an independent, Italian, and research-based pharmaceutical company, pioneer since 1918 in the development, production and marketing of medicines worldwide.

IBI has developed a diverse portfolio of products for export and third parties, using innovative technologies and is certified by FDA, AIFA, EDQM, TGA and PMDA

Development and GMP manufacturing of parenteral formulation is the main task of IBI. The Company has a strong expertise in development and scaling-up for GMP production of formulations, also based on innovative delivery systems (nano and microparticles) and lyophilisation processes.

The R&D Department is able to develop innovative formulations, for all the routes of administration, both for small molecules and for biotechnological APIs. In accordance with the most recent guidelines and the most modern development methodologies, IBI’s R&D Laboratories adopt “Quality by Design” approach for optimization of production processes.

The Company is also authorized to produce biotechnological substances (recombinant proteins, antibodies) and medicinal products for investigational use.

Loredana has thirty years of experience in Pharmaceutical Research & Development. In 1987, she graduated in Chemistry at the University of Rome. Since 2006, she has been the Director of Research and Development of IBI. Today, her team deals with all the activities related to internal R&D projects and Contract Development and Manufacturing, from laboratory trials to GMP production of Investigational Medicinal Products. She is also responsible of the Biotechnology Department, where fermentation and purification processes, from mammalian cells, are developed

Giovanni Esposito is Product Development Leader within R&D Laboratories. He deals with formulation development and GMP scaling-up of pharmaceutical finished products, oral and injectable forms, such as sterile solutions or freeze-dried powders. The whole development, from analytical and manufacturing validation to stability studies, is performed by a Quality Risk Management approach and with the application of QbD methodologies.

His expertise covers also the development of innovative formulations, based on nano and microparticles systems.

Christophe Egles


CNRS mixed research unit 7338 BioMechanic and BioIngineering (BMBI)

The laboratory research activities focus on the mechanics of the living and engineering strategies for health and body repair. The specificity of BMBI is its multidisciplinary nature which translates as interdisciplinary research combining mechanical skills, physical projects, signal processing, (cell and molecular) biology, biochemistry, or physiology.

Christophe Egles, is, since 2010 Professor at Université de Technologie de Compiègne, (France). He is the co-head of the research group Cell, Biomaterials Bioreactor in the CNRS unit Biomechanics and Bioengineering (UMR CNRS 7338). Christophe Egles earned his B.S. in Biochemistry and his Ph.D. in Neurobiology at the University Louis Pasteur in Strasbourg, France. From 2001 to 2004, he served as Associate Professor at the University Louis Pasteur, School of Dentistry where he studied the biomedical applications of biomaterials modifying cell/support interface. From 2005 to 2010 he joined Tufts University in the Division of Cancer Biology and Tissue Engineering as an Assistant Professor and served as the Associate Director of the Center for Integrated Tissue Engineering. He is an expert of tridimensional culture systems for Regenerative Medicine. His research focuses on the development of human skin–equivalent for the preclinical development and testing of new wound healing agents, as well as new biofunctionalized artificial matrices for the reparation of central nervous system.

Muriel Cario-Andre


Physiopathology of pigmentation and tissue engineering, INSERM 1035

Our project has two mains goal. The first one consists to study the pathophysiology of the dermo-epidermal melanin unit using as model various skin diseases. We are focalized on the role of dermal compartment mostly fibroblasts in regulation of pigmentation and epidermal differentiation. Our model for studying this effect is systemic scleroderma, a fibrotic disease due to excessive production of collagen by fibroblasts associated for 43 % of patients which hypo or hyperpigmentary disorders. Another disease of particular interest is vitiligo which is due to a chronic loss of melanocytes. Due to close contact with the National reference center for rare skin disease and collaboration with cosmetic industries, we try to understand and reproduce other rare skin diseases (Cole disease) and frequent pigmentary disorders such as lentigo senile and melasma.

The second focused on regenerative medicine, we created an autologous pigmented skin obtained after amplification of cutaneous cells (patent WO2016151134A1) which is now in preclinical step. This graft could be used for burnt patients, reconstructive surgery post-tumor or dermatological disorders such as giant naevi or on hypopigmentary disorders (piebaldism, vitiligo).

Muriel Cario-Andre earned is PhD in Biology and Medical Sciences at the University Victor segalen in Bordeaux, France. She has more than 20 years of experience in pathophysiology of human skin pigmentation and tissue engineering. She is a board member of the European society for pigment cell research (ESPCR) and from the GDR Cosm’actifs. She is the team leader of the “Physiopathology of pigmentation and tissue engineering group” of INSERM 1035. She collaborates with academic teams especially on melanoma research and Cosmetic Industries on pigmentation and skin aging. Dr. Cario-Andre is the co-manager of Aquiderm a technology transfer unit specialized in skin engineering and evaluation of efficacy of cosmetic products (pigmenting, depigmenting, photoprotective). She developed a pigmented skin equivalent (WO2016151134 A1. EP3072535 B1), which is under preclinical evaluation. Fields of expertise include: primary cell cultures, pigmentary disorders, dermal -epidermal interactions, photoprotection, skin modelling (diseases cells or genetically modified cells) and skin anatomopathology.

Abhay Pandit


Centre for Research in Medical Devices (CÚRAM)

National University of Ireland, Galway (NUI Galway)

CÚRAM is a multidisciplinary research centre advancing R&D in the medical device sector. Supported by Science Foundation Ireland and industry partners, CÚRAM enhances Ireland’s standing as a major hub for the global medical devices industry. It aims to create a sustainable future for the MedTech sector in Ireland and train the next generation of world class MedTech scientists and entrepreneurs. CÚRAM’s research programme focuses on innovative design, assessment and manufacture of medical devices and is driven by specialist researchers, clinicians and industry partners, ultimately translating research into clinical settings. Over 200 researchers are engaged in developing innovative implantable ‘smart’ devices to respond to the body’s environment and to deliver therapeutic agents exactly where they are needed. CÚRAM’s devices are developed with strong clinical collaborations to enable rapid translation of research findings to clinical application. The research benefits patients with chronic ailments such as soft tissue and wound healing, cardiovascular, neural, renal, pulmonary, ophthalmology and musculoskeletal diseases. Underpinning these disease targets are core research capabilities in biomaterials, drug delivery, cell therapy, glycosciences and device design. The ultimate goal is to provide affordable transformative solutions for chronic diseases.

Professor Abhay Pandit is the Established Professor in Biomaterials. He is the Director of a Science Foundation Ireland funded Centre for Research in Medical Devices (CÚRAM) at the National University of Ireland, Galway. Prof. Pandit has over twenty-five years of experience in the field of biomaterials. He has published more than 180 papers in peer-reviewed journals, filed numerous patent applications and has licensed four technologies to medical device companies. Prof. Pandit’s research program develops hierarchical biomaterial constructs coupled with tailored functionalisation strategies integrating material science and biological paradigms in developing solutions for chronic disease.